Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?

by Hans C. Hasselbalch
Published 2020-06-01

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art

by Sylvie Hermouet, Hans C. Hasselbalch, Vladan Čokić
Published 2015-01-01

Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus

by Arthur E. Frankel, Wai C. Yip, Eknath Naik, Hans C. Hasselbalch
Published 2021-06-01

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives

by Hans C. Hasselbalch, Vibe Skov, Lasse Kjær, Torben L. Sørensen, Christina Ellervik, Troels Wienecke
Published 2020-08-01

Statin treatment, oxidative stress and inflammation in a Danish population

by Anders L. Sørensen, Hans C. Hasselbalch, Claus H. Nielsen, Henrik E. Poulsen, Christina Ellervik
Published 2019-02-01

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study

by Anders L. Sørensen, Hans C. Hasselbalch, Mads Emil Bjørn, Claus H. Nielsen, Sabrina Cordua, Vibe Skov, Lasse Kjær, Henrik E. Poulsen, Christina Ellervik
Published 2021-05-01

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

by Lasse Kjær, Sabrina Cordua, Morten O Holmström, Mads Thomassen, Torben A Kruse, Niels Pallisgaard, Thomas S Larsen, Karin de Stricker, Vibe Skov, Hans C Hasselbalch
Published 2016-01-01

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

by Arthur E. Frankel, Renuka Reddy, Kayla R. DeSuza, Khaled Deeb, Aaron F. Carlin, Davey Smith, Yushuang Xie, Eknath Naik, Richard T. Silver, Hans C. Hasselbalch
Published 2021-04-01

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care

by Sarah F. Christensen, Robyn M. Scherber, Gina L. Mazza, Amylou C. Dueck, Nana Brochmann, Christen L. Andersen, Hans C. Hasselbalch, Ruben A. Mesa, Holly L. Geyer
Published 2021-06-01

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms

by Rasmus K. Pedersen, Morten Andersen, Trine A. Knudsen, Zamra Sajid, Johanne Gudmand‐Hoeyer, Marc J. B. Dam, Vibe Skov, Lasse Kjær, Christina Ellervik, Thomas S. Larsen, Dennis Hansen, Niels Pallisgaard, Hans C. Hasselbalch, Johnny T. Ottesen
Published 2020-03-01

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

by Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group
Published 2020-12-01